Mark Andersen

Mark Andersen

Director of Finance/CFO presso FIBROBIOLOGICS, INC.

53 anni
Health Technology
Commercial Services
Consumer Services

Profilo

Mark Andersen is currently the Chief Financial Officer at FibroBiologics, Inc. He previously worked as the Investments Director-Pension Plan at Eli Lilly & Co. from 2004 to 2015, Vice President-Finance & Controller at MiMedx, Inc. from 2015 to 2016, Head-Controller at Lilly USA LLC, Auditor at Deloitte Development LLC from 1998 to 1999, and Auditor at KPMG US LLP from 1996 to 1998.
He also served as the Chief Financial Officer & VP-Administration at Indiana Biosciences Research Institute from 2016 to 2022.
Andersen received his undergraduate and graduate degrees from Southern Utah University and his MBA from Stephen M.
Ross School of Business.

Posizioni attive di Mark Andersen

SocietàPosizioneInizio
FIBROBIOLOGICS, INC. Director of Finance/CFO 01/06/2022
Tutte le posizioni attive di Mark Andersen

Precedenti posizioni note di Mark Andersen

SocietàPosizioneFine
Director of Finance/CFO 01/05/2022
Director of Finance/CFO 01/02/2016
ELI LILLY AND COMPANY Corporate Officer/Principal 01/08/2015
Comptroller/Controller/Auditor 01/01/1999
Comptroller/Controller/Auditor 01/01/1998
Vedi nel dettaglio l'esperienza di Mark Andersen

Formazione di Mark Andersen

Southern Utah University Graduate Degree
Stephen M. Ross School of Business Masters Business Admin

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Mark Andersen

Relazioni

100 +

Relazioni di 1° grado

9

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa2
ELI LILLY AND COMPANY

Health Technology

FIBROBIOLOGICS, INC.

Health Technology

Aziende private5

Health Technology

Commercial Services

Commercial Services

Commercial Services

Health Technology

Vedi le connessioni aziendali